Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494285 | 0.81 | ROCK2 (0.34) | — | |
| SCHEMBL17494449 | 0.79 | SOS1 (0.48) | SOS1CGASCFTRMAPK1 | |
| SCHEMBL19195364 | 0.79 | SOS1 (0.48) | SOS1CGASCFTRMAPK1 | |
| SCHEMBL17494506 | 0.78 | OPRK1 (0.30) | — | |
| SCHEMBL32669454 | 0.73 | SOS1 (0.50) | SOS1CGASCFTRPOLB | |
| SCHEMBL17494244 | 0.71 | SOS1 (0.51) | SOS1CGASCFTRPOLB | |
| Hydrochloric Acid SCHEMBL20549472 | 0.71 | SOS1 (0.41) | SOS1CGASCFTR | |
| SCHEMBL17494279 | 0.70 | SOS1 (0.50) | SOS1CGASCFTRPOLB | |
| SCHEMBL15543439 | 0.70 | SCN9A (0.41) | — | |
| SCHEMBL20549477 | 0.70 | SOS1 (0.38) | SOS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | SOS1 2618/4885CGAS 10/4885CFTR 254/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | SOS1 2618/4885CGAS 10/4885CFTR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.